… therefore necessitate treatment with an erlotinib dose greater … on the erlotinib BR.21 data,
(e) the vast majority of lung cancer … from erlotinib-based interventions for advanced lung cancer …

… Despite treatment advances, lung cancer remains the leading cause of cancer-related …
Cytotoxic chemotherapy has been the backbone of treating advanced non–small-cell lung cancer (…

… (first-line therapy) for patients with a new diagnosis of EGFR-mutated lung cancer. This …
In conclusion, this trial of concurrent erlotinib and radiation therapy for the initial treatment of …

… In the future, it is recommended that the two methods are combined to treat non-small-cell
lung cancer patients with brain metastases. However, the optimal combination of the two types …

… implicated in cell proliferation and survival. , 2 Erlotinib is currently approved for the treatment
of chemorefractory non–small-cell lung cancer (NSCLC) and maintenance therapy after …

… Eligibility criteria were age 18 years and older, histology or cytology confirmed diagnosis
of lung cancer for which treatment with erlotinib monotherapy was indicated, use of erlotinib …

… The phase I study explored the treatment of lung cancer cells with a combination of
erlotinib and permetrexed, which was well-tolerated and fairly successful in antitumor efficacy (…

… nonsmall-cell lung cancer who receive erlotinib, the presence of … in the study treatment with
erlotinib through Tarceva EAP (… like to present a case of our first patient treated with erlotinib. …

… of erlotinib treatment were compared with nonprogression measured by computed
tomography after 6 weeks of treatment, progression-free survival (PFS), and overall survival (OS). …

… Reported incidence of ILD events in patients treated with gefitinib or erlotinib varied
substantially among trials. In a phase II study by Niho et al. in patients with NSCLC, four (10.0%) of …